Skip to main content
Grant Details

Grant Number: 5U01CA195568-04 Interpret this number
Primary Investigator: Cerhan, James
Organization: Mayo Clinic Rochester
Project Title: The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Fiscal Year: 2018
Back to top


Abstract

? DESCRIPTION (provided by applicant): In 2014, an estimated 70,800 people in the US will be diagnosed with non-Hodgkin lymphoma (NHL), and 18,990 will die from this cancer. NHL incidence rates increased over the last half of the 20th century and only recently stabilized. In parallel, NHL survival rates began improving in the mid-1990s with the advent of improved treatment strategies, leading to the current 5-year survival rate of 69 percent. These trends have led to a growth in the number of NHL survivors, estimated at over 650,000 in 2010. To address the current and long-term unmet health needs of this growing patient population, we propose to establish the Lymphoma Epidemiology of Outcomes (LEO) cohort study, which will expand an ongoing cohort of over 4,000 NHL patients that was established in 2002. The goal of expanding this infrastructure to over 12,000 NHL patients is to support a broad research agenda aimed at identifying novel clinical, epidemiologic, host genetic, tumor, and treatment factors that significantly influence NHL prognosis and survivorship. To meet these goals, over the next 5 years we propose to: 1) Expand recruitment to six new centers, with a goal of recruiting 8,700 newly diagnosed NHL patients (including 1,000 African American and 1,400 Hispanic participants), for a total cohort of 12,900 patients (including 3,700 diffuse large B-cell and 3,30 follicular lymphomas); 2) Review all pathology diagnoses and build a NHL tumor bank that includes an H&E slide, a formalin-fixed, paraffin-embedded tissue samples, and extracted tumor DNA and RNA; 3) Collect a peripheral blood sample and bank DNA, serum, plasma and buffy coat in a central biorepository; 4) Annotate and harmonize all cases with clinical, epidemiologic, pathology and treatment data; 5) Prospectively follow patients in the cohort regularly to ascertain disease progression/relapse, retreatment, transformation, second cancers, survival (including cause of death), updated exposures, patient-reported outcomes (PROs), and other long-term health outcomes; and 6) Facilitate research projects that use this infrastructure and promote interactions with lymphoma clinical trial networks. We will achieve these aims through close coordination of each of the participating centers, supported by four cores (Administration; Clinical; Pathology & Biospecimens; and Biostatistics & Informatics). These cores will also conduct methodological research to enhance data collection, patient follow-up, biospecimen science and statistical modeling. The proposed LEO cohort infrastructure overcomes limitations of other study designs, is feasible, and will be used to improve diagnosis, risk stratification, treatment, and short and long-term management of NHL patients. The LEO investigators will leverage this resource to foster discovery and validation of novel biologic and clinical insights. LEO will be led by international leaders in clinical and epidemiologic research on NHL thereby driving the translation of new findings to the clinic and the population.

Back to top


Publications

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Authors: Bachy E. , Maurer M.J. , Habermann T.M. , Gelas-Dore B. , Maucort-Boulch D. , Estell J.A. , Van den Neste E. , Bouabdallah R. , Gyan E. , Feldman A.L. , et al. .
Source: Blood, 2018-07-05 00:00:00.0; 132(1), p. 49-58.
EPub date: 2018-04-17 00:00:00.0.
PMID: 29666118
Related Citations

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
Authors: Maurer M.J. , Ghesquières H. , Link B.K. , Jais J.P. , Habermann T.M. , Thompson C.A. , Haioun C. , Allmer C. , Johnston P.B. , Delarue R. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2018-06-01 00:00:00.0; 36(16), p. 1603-1610.
EPub date: 2018-04-19 00:00:00.0.
PMID: 29672223
Related Citations

Human Pegivirus infection and lymphoma risk and prognosis: a North American study.
Authors: Fama A. , Xiang J. , Link B.K. , Allmer C. , Klinzman D. , Feldman A.L. , Nowakowski G.S. , Liebow M. , Larson M.C. , Maurer M.J. , et al. .
Source: British Journal Of Haematology, 2018-05-29 00:00:00.0; , .
EPub date: 2018-05-29 00:00:00.0.
PMID: 29808922
Related Citations

Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors.
Authors: Keegan T.H.M. , Li Q. , Steele A. , Alvarez E.M. , Brunson A. , Flowers C.R. , Glaser S.L. , Wun T. .
Source: Cancer Causes & Control : Ccc, 2018-04-13 00:00:00.0; , .
EPub date: 2018-04-13 00:00:00.0.
PMID: 29654427
Related Citations

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.
Authors: Ravi P. , Kumar S.K. , Cerhan J.R. , Maurer M.J. , Dingli D. , Ansell S.M. , Rajkumar S.V. .
Source: Blood Cancer Journal, 2018-02-28 00:00:00.0; 8(3), p. 26.
EPub date: 2018-02-28 00:00:00.0.
PMID: 29531285
Related Citations

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
Authors: El-Galaly T.C. , Cheah C.Y. , Bendtsen M.D. , Nowakowski G.S. , Kansara R. , Savage K.J. , Connors J.M. , Sehn L.H. , Goldschmidt N. , Shaulov A. , et al. .
Source: European Journal Of Cancer (oxford, England : 1990), 2018-02-21 00:00:00.0; 93, p. 57-68.
EPub date: 2018-02-21 00:00:00.0.
PMID: 29477102
Related Citations

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Authors: Huet S. , Tesson B. , Jais J.P. , Feldman A.L. , Magnano L. , Thomas E. , Traverse-Glehen A. , Albaud B. , Carrère M. , Xerri L. , et al. .
Source: The Lancet. Oncology, 2018-02-20 00:00:00.0; , .
EPub date: 2018-02-20 00:00:00.0.
PMID: 29475724
Related Citations

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression.
Authors: Tracy S.I. , Habermann T.M. , Feldman A.L. , Maurer M.J. , Dogan A. , Perepu U.S. , Syrbu S. , Ansell S.M. , Thompson C.A. , Weiner G.J. , et al. .
Source: Haematologica, 2018 Feb; 103(2), p. 297-303.
EPub date: 2017-11-23 00:00:00.0.
PMID: 29170255
Related Citations

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
Authors: Maurer M.J. , Ellin F. , Srour L. , Jerkeman M. , Bennani N.N. , Connors J.M. , Slack G.W. , Smedby K.E. , Ansell S.M. , Link B.K. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2017-12-20 00:00:00.0; 35(36), p. 4019-4026.
EPub date: 2017-10-26 00:00:00.0.
PMID: 29072976
Related Citations

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.
Authors: Cerhan J.R. , Link B.K. , Habermann T.M. , Maurer M.J. , Feldman A.L. , Syrbu S.I. , Thompson C.A. , Farooq U. , Novak A.J. , Slager S.L. , et al. .
Source: International Journal Of Epidemiology, 2017-12-01 00:00:00.0; 46(6), p. 1753-1754i.
PMID: 29025017
Related Citations

Early Relapse in Follicular Lymphoma: High Risks and High Stakes.
Authors: Link B.K. .
Source: Journal Of Oncology Practice, 2017 Dec; 13(12), p. 810-811.
PMID: 29232540
Related Citations

Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
Authors: Koff J.L. , Flowers C.R. .
Source: Cancer, 2017-09-01 00:00:00.0; 123(17), p. 3222-3225.
EPub date: 2017-05-02 00:00:00.0.
PMID: 28464215
Related Citations

Evaluating Surveillance Imaging For Diffuse Large B-cell Lymphoma And Hodgkin Lymphoma
Authors: Cohen J.B. , Behera M. , Thompson C.A. , Flowers C.R. .
Source: Blood, 2017-02-02 00:00:00.0; 129(5), p. 561-564.
PMID: 27956385
Related Citations

B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.
Authors: Koff J.L. , Flowers C.R. .
Source: Expert Review Of Hematology, 2016 Jun; 9(6), p. 553-61.
PMID: 27098121
Related Citations

Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies.
Authors: Glass S. , Phan A. , Williams J.N. , Flowers C.R. , Koff J.L. .
Source: Discovery Medicine, 2016 Mar; 21(115), p. 181-8.
PMID: 27115168
Related Citations

Next-generation prognostic assessment for diffuse large B-cell lymphoma.
Authors: Staton A.D. , Koff J.L. , Chen Q. , Ayer T. , Flowers C.R. .
Source: Future Oncology (london, England), 2015; 11(17), p. 2443-57.
PMID: 26289217
Related Citations




Back to Top